丹麦企业受益于中国知识产权同等保护|知识产权_新浪财经

Danish company benefits from intellectual property equal protection in China

　　Amidst the global wave of the biotechnology revolution, which is rapidly integrating into economic and social development, new solutions are emerging to tackle significant challenges such as health, climate change, resource and energy security, and food security. Novonesis, headquartered in Denmark and formed through the merger of two long-established companies, Novozymes and Chr. Hansen, is one of the leading enterprises in this sector. Not only has Novonesis accumulated extensive innovative achievements in the biomanufacturing industry, but it has also developed a robust intellectual property (IP) management system and protection strategies, gaining substantial experiences in IP transformation and dealing with IP infringements. Recently, CIPNews' reporters visited Novonesis' China headquarters to explore how foreign enterprises are having benefit of IP equal protection in China.

　　Novonesis entered Chinese market as early as the 1970s and focused on establishing a strong presence in China during the 1990s by setting up research and development centers and production bases. "Novonesis's research center in Beijing was one of the first R&D centers established by a foreign biotech company in China," said Wang Cong, Director of Government Affairs and Public Relations of Novonesis Asia-Pacific. Currently, Novonesis has established comprehensive industrial structure and systems in China, spanning from R&D to production and supply chains across six cities.

　　Dr. Wu Wenping, Chief Scientist of Novonesis Asia-Pacific, explained that after entering the Chinese market, the company closely followed China's economic development and the needs of its people, continuously launching innovations and applications tailored to the local market. In recent years, Novonesis has driven technological innovation centered around enzymes, microorganisms, and proteins, promoting sustainable development across multiple industries, including food and beverages, and bioenergy.

　　"New quality productive forces are the new track for competition. The biotechnology industry has become one of the strategic emerging industries of China, and we are looking forward to the vigorous development of China's bioeconomy," said Wang. She noted that China has many advantages in developing biotechnology: a large market with significant potential; a complete industrial chain in the biotechnology sector, including the world's largest fermentation capacity; active R&D innovation from numerous universities, research institutions, and startups in biomanufacturing; and government support for industrial innovation through improved laws and regulations.

　　Recognizing the importance of continuous innovation and understanding industry trends, Novonesis fully understands that a strong IP system is crucial for sustained innovation in society. "As an R&D-driven company, we invest approximately 10% of our annual revenue into research and development, and we have established an incentive mechanism for inventors to encourage innovation. Currently, we own hundreds of registered trademarks and 9,900 valid patents worldwide," said Zhang Yan, Head of IPO of Novonesis China. "Globally, we have an IP team of over 80 people, spreading across multiple regions, responsible for IP applications, operations, and management."

　　"In recent years, we have clearly felt that China's patent examination system is continuously improving, with increased efficiency and strengthened IP protection, all of which contribute to the source protection of innovative achievements," said Zhang. Novonesis was one of the first biotech companies to have its IP rights successfully validated and enforced in China, thanks to the IP authorities' focus on refining examination policies based on the needs of innovators. During this process, Novonesis actively cooperated with the Chinese government to improve patent examination standards in the field of biomolecules. The invalidation case involving the company's patent on "thermostable glucoamylase" was selected as one of China's top ten typical IP cases by the courts.

　　Earlier this year, four final judgments from China's Supreme People's Court significantly boosted Novonesis' confidence in pursuing IP judicial protection in China, further solidifying the company's commitment to investing in the country. "The success of these cases not only marks a significant milestone in protecting our innovations, but also brings encouraging news to the entire biotechnology industry," said Xie Danfang, Director and Head of Regional Legal of Novonesis Asia-Pacific. "The trial experience in these cases has deeply impressed us with China's continuously improving IP judicial system, the increasing severity of penalties for IP infringement, and the equal protection of IP rights for both domestic and foreign right holders in China."

　　Having operated in the Chinese market for many years, Novonesis has also benefited from China's unique IP protection system. In the meantime, the company has expectations regarding the execution of judicial rulings, administrative filing standards, burden of proof, and the coordination between judicial and administrative protection, which they hope that the IP system and protection mechanisms will operate more swiftly and efficiently in the future, and that more severe penalties for malicious infringers will better deter IP violations. "Compared to when we first entered China, the awareness of IP protection across all sectors of Chinese society has significantly improved. We hope that China will continue to leverage the advantages of its IP system to ensure the long-term benefits for the biotechnology industry," Xie summarized. (by Wang Yu/Wang Jing)

　　当前，生物技术革命浪潮席卷全球并加速融入经济社会发展，为人类应对生命健康、气候变化、资源能源安全、粮食安全等重大挑战提供了崭新的解决方案。总部位于丹麦的诺和新元集团（下称诺和新元）就是代表性企业之一。由诺维信和科汉森两家历史悠久的企业合并而成的诺和新元，不仅在生物制造行业积淀了丰富的创新成果，还凭借完善的知识产权管理体系、保护策略，在知识产权转化和应对知识产权侵权方面积累了丰富经验。近日，中国知识产权报记者走进诺和新元中国区总部，实地探访外资企业在中国获得知识产权“同等保护”的生动实践。

　　早在20世纪70年代，诺和新元就进入中国市场，到90年代集中在中国布局，并设立了研发中心和生产基地。“诺和新元位于北京的中国研发中心是外资生物技术企业中较早在华创办的研发中心。”诺和新元亚太区政府事务和公共关系总监王聪介绍，目前诺和新元在中国6个城市形成了从研发到生产再到供应链非常完整的产业布局和工业体系。

　　诺和新元亚太区首席科学家吴文平介绍，企业进入中国市场后，紧跟中国的经济发展步伐和百姓社会生活的需求，不断推出适合本地市场需求的创新和应用。近几年来，诺和新元以酶、微生物、蛋白质为核心，进行技术革新，推动食品和饮料、生物质能源等多产业多领域可持续发展。

　　“新质生产力是竞争的新赛道。生物产业成为中国的战略性新兴产业之一，我们对中国生物经济的蓬勃发展充满期待。”在王聪看来，中国在发展生物技术方面拥有诸多优势：一是具有庞大的市场和潜力；二是在生物产业领域拥有完整的产业链、全球最大生物发酵产能；三是众多高校、科研机构及初创型企业在生物制造领域的研发创新活跃；四是中国政府注重通过完善法律法规和规章制度，支持产业的创新发展。

　　基于对创新的持续投入和行业发展趋势的洞察，诺和新元深知，知识产权制度的保驾护航是整个社会持续创新的关键。“作为一家研发驱动型公司，我们每年将营业额的大约10%投入研发，并设有发明人奖励和报酬机制，鼓励创新。目前，公司在全球拥有数百件注册商标和9900件有效专利。”诺和新元中国区知识产权部门负责人张艳介绍，“在全球范围内，我们拥有一支80多人的知识产权团队，分布在全球多个地区，负责知识产权申请、运营及管理等系列工作。”

　　“近年来，我们明显感觉到中国专利审查体系在不断完善，专利审查效率持续提高，知识产权保护力度持续加强，这些都有助于创新成果的源头保护。”张艳介绍，诺和新元是生物科技领域较早在华成功进行知识产权确权和维权的公司，这源于中国的知识产权管理部门注重从创新主体的需求出发完善相关审查政策。在此过程中，诺和新元也积极配合中国政府有关部门完善生物大分子领域的专利审查标准，涉该公司的“热稳定的葡糖淀粉酶”专利无效案入选中国法院十大知识产权典型案件。

　　今年年初，4份来自中国最高人民法院的终审判决，大大提振了诺和新元在华进行知识产权司法保护的信心，进一步稳定了诺和新元在华投资的决心。“这些案件的胜诉不仅成为我们自身保护创新成果的重要里程碑，同时对整个生物技术产业来说，也是非常振奋的消息。”诺和新元亚太区法务总监谢丹放表示。“上述案件的审理过程，让我们深刻感受到中国的知识产权审判制度不断完善，知识产权侵权行为惩处力度不断加大，中外权利人的知识产权在华获得了同等保护。”谢丹放表示。

　　进入中国市场多年，诺和新元也从具有中国特色的知识产权保护体系中获益。与此同时，在司法判决执行、行政立案标准、举证责任及司法和行政联动保护等方面，企业也表达了新的期待，希望未来知识产权制度和保护体系能更加快捷、高效地运行。同时，强化对恶意侵权人的失信惩戒力度，更好阻遏侵权行为发生。“与刚进入中国时相比，当前中国社会各界的知识产权保护意识有了极大的提升，希望未来中国能够更好地发挥知识产权的制度优势，让生物技术行业长期从中受益。”谢丹放表示。（王宇王晶）

（编辑：晏如责任编辑：吕可珂审校：冯飞）